Technology
Health
Pharmaceutical

MEI Pharma

$1.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-3.95%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell MEI Pharma and other stocks, options, ETFs, and crypto commission-free!

About MEIP

MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Read More Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Employees
32
Headquarters
San Diego, California
Founded
2000
Market Cap
126.17M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
552.34K
High Today
$1.80
Low Today
$1.70
Open Price
$1.80
Volume
419.89K
52 Week High
$4.80
52 Week Low
$1.70

Collections

Technology
Health
Pharmaceutical
Medical
Cancer Prevention
US
North America

MEIP Earnings

-$0.36
-$0.28
-$0.20
-$0.12
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Aug 29, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.